Prevention of mother-to-child transmission successes in resource-rich countries
In 1994, a landmark Pediatric AIDS Clinical Trials group study (PACTG 076) demonstrated a 67% reduction in perinatal HIV transmission with the administration of a combination of prenatal, intrapartum, and neonatal zidovudine [5] . The US Public Health Task Force adopted the study's finding and recommended that all pregnant women should be offered HIV testing, and those women who were identified as HIV-infected should be given the three-part zidovudine regimen (i.e., the PACTG 076 regimen). There is an increase in the acceptance and completion of rapid HIV testing in resource-rich countries [6 ] .
Perinatal transmission rates as low as 1% have been achieved as a result of the use of the PACTG 076 regimen (Table 2) [7] , highly active antiretroviral therapy (HAART) regimens, and appropriate management of labor and delivery. Therefore, the birth of an infected child in a resource-rich country is now a sentinel health event signaling a chain of missed opportunities and barriers to available PMTCT programs [8] . The Centers for Disease Control and Prevention estimates that 100-200 infants with HIV infection are born in the United States annually. The rate of MTCT of HIV continues to decrease; in 2005, only about 67 HIV-infected infants were born in the United States [9] .
Prevention of mother-to-child transmission challenges in resource-rich countries
There are ongoing issues that may reverse or threaten the gains achieved in PMTCT of HIV in resource-rich countries.
Late access to mother-to-child transmission prevention services
In a French study, it was observed that pregnant women who have emigrated from sub-Saharan African countries had delayed access to HIV testing and antenatal care as compared with French-born pregnant women [10 ] . In the United States, racial/ethnic differences in the time to initiation of HAART have been observed among HIVinfected pregnant women; 42% of white women started therapy prior to pregnancy as compared with 29% of Mother-to-child transmission of HIV Paintsil and Andiman 95 Hispanic and 27% of black women [11] . Moreover, the number of teenagers who were perinatally infected, are nonadherent to their HAART regimens, and who access care very late in pregnancy is on the rise.
Nonadherence to HIV testing guidelines during pregnancy by providers
There are some providers who continue to offer routine HIV testing during pregnancy solely to women they consider at high risk, rather than to all pregnant women. There are cases of infected infants born to women who tested negative in early pregnancy but who seroconverted later in pregnancy, presumably as a result of recent acquisition of primary infection.
Herpes simplex virus type 2 coinfection and the risk of mother-to-child transmission of HIV Genital ulcer diseases, including herpes simplex virus type 2 (HSV-2) and syphilis, facilitate sexual transmission and acquisition of HIV. HSV-2 coinfection with HIV results in increased genital shedding of HIV [12] . It is postulated that HSV-2 coinfection may increase the risk of MTCT of HIV. In a case-control study of HIVinfected women enrolled in an MTCT trial in Zimbabwe, HSV-2 infection was associated with increased intrapartum MTCT of HIV [adjusted odds ratio, 1.50; 95% confidence interval (CI), 1.09-2.08] [13 ] . The administration of valaciclovir (which suppresses subclinical and clinical reactivation of HSV-2) to HIV-infected women reduced their genital and plasma HIV viral loads [14 ] . Further research is needed to determine whether treatment of HSV-2 coinfection in HIV-infected pregnant women will result in further reduction of MTCT of HIV.
Effect of perinatal antiretroviral exposure on infants
There are limited data on the short-term and long-term toxicities associated with exposure of an infant to antiretroviral drugs in utero and during infancy. In a long-term study (4-6 years), no adverse events were observed with in-utero exposure to zidovudine; however, there were occasional episodes of transient and self-limiting anemia [15] . The Women And Infants Transmission Study (WITS) group recently reported small but significant differences in several hematologic parameters in the first 24 months of life between infants exposed and unexposed to perinatal antiretrovirals [16] . There is a need for continuous surveillance of infants exposed in utero to combination antiretroviral therapy for emergence of adverse events.
Drug-resistant HIV and its impact on mother-to-child transmission
In a recent study (PACTG P1030), about a quarter of a cohort of recently infected US-born infants were infected with drug-resistant HIV [17 ] . Moreover, postnatal treatment of an infant to prevent MTCT may select for drug-resistant HIV acquired from the mother [18] . Resistant virus may be archived in the resting CD4 þ T cells of the infants within the first 6 months [17 ] . Although not statistically significant, children with drug-resistant virus tended to have a poor treatment outcome. Moreover, poor virologic response to nevirapine-containing HAART regimens in the postpartum period has been observed in HIVinfected women exposed to intrapartum nevirapine [19] .
Prevention of mother-to-child transmission successes in resource-limited countries
In resource-limited countries, a number of randomized trials have assessed the efficacy of short-course antiretrovirals (sc-ARVs) to reduce MTCT of HIV (Table 2 ) [7] . WHO recommends either the use of combination antiretroviral treatment (usually including nevirapine) for pregnant women in need of treatment for their own health or the administration of short-course zidovudine (sc-ZDV) followed by single-dose nevirapine (SDNVP) during labor or a 7-day postpartum short course of zidovudine and lamivudine if antiretroviral treatment is not yet indicated [20] . However, SDNVP administered to the mother at labor and to the infant within 48-72 h of life is the most popular regimen because of the ease of administration and low cost ( Table 2) . Efficacy of short-course antiretroviral regimens to prevent mother-to-child transmission
The efficacy of sc-ARV varies from country to country because of differences in PMTCT coverage, components, and available antiretroviral regimens ( [22 ] .
The Drug Resource Enhancement against AIDS and Malnutrition program demonstrated that PMTCT outcomes can be improved significantly if programs to protect the unborn child are accompanied by antiretroviral treatment of the mother's infection [23] . Transmission rates were compared between two cohorts of pregnant women. The first cohort gave supplemental formula to their infants for the first 6 months after delivery, and the second cohort received HAART during the first 6 months while exclusively breast-feeding [24 ] . MTCT rates were 4/341 (1.2%) and 7/809 (0.8%) among formula-fed and breast-fed infants at 1 month of age, respectively. Tonwe-Gold et al.
[25 ] evaluated a two-tiered PMTCT strategy in which treatment was selected on the basis of maternal medical status (as indicated by CD4 þ T cell count and WHO clinical staging) in pregnant women enrolled in Abidjan, Cote d'Ivoire, in the MTCT-Plus initiative. The first cohort included 107 women who received HAART (combination of zidovudine, lamivudine, and nevirapine) at a median gestational age of 30 weeks and continued treatment postpartum. The second cohort of 143 women was not eligible for HAART, and they received sc-ARV (combination of zidovudine and lamivudine with SDNVP during labor) for PMTCT. The rate of peripartum HIV transmission was 2.2%, the cumulative rate of infant HIV infection at 12 months was 5.7%, and the 12-month HIV-free survival was 88.3%, without significant difference between the two groups. 
Prevention of mother-to-child transmission challenges in resource-limited countries
The obstacles facing PMTCT programs in resourcelimited countries are multifaceted: lack of healthcare infrastructure, slow integration of PMTCT programs to traditional maternal child health (MCH) services, limited manpower, limited donor funding, and competing public health priorities with limited healthcare budget [29 -31 ].
Low coverage of antiretroviral treatment and mother-tochild transmission programs
At the end of 2007, 55 of 136 (40.4%) countries had less than 25% coverage of antiretrovirals to adults and children with advanced AIDS [1]. Moreover, 61 of 113 resource-limited countries had less than 25% coverage of antiretrovirals for PMTCT ( . Routine offer of antenatal HIV counseling and testing ('opt-out' approach) and availability of rapid HIV kits in antenatal care and labor ward could improve the coverage and uptake of PMTCT among pregnant women [32 ,33 ] .
Development of drug-resistant HIV to prevention of mother-to-child transmission antiretroviral agents
A 5-year follow-up study of the HIV Network for Prevention 012 Trial to examine the persistence of the mutation at codon 103 of the reverse transcriptase gene from 'lysine' to 'asparagine' (K103N) in women who received SDNVP found that, of the 60 women who harbored the K103N mutation, 16, 43, 55, and 55 women demonstrated fading of the mutation by 2, 3, 4, and 5 years, respectively [34 ] . The K103N mutation confers resistance to HIV nonnucleoside analogs. For women who were reexposed to SDNVP for PMTCT, the detection of K103N was independently associated with its detection at 6-8 weeks after the first SDNVP exposure and prenevirapine viral load [35 ] . Recent studies suggest that treatment with a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen may still be effective in SDNVP-exposed women, provided that treatment is not initiated too soon (<6 months) after SDNVP exposure [36 ,37 ] . Combination of other antiretrovirals with SDNVP reduces the emergence of NNRTI-associated resistance mutations. The addition of intrapartum and 4-7 days of maternal postpartum zidovudine/lamivudine significantly reduced the prevalence of NNRTI-associated resistant mutations [38 ] . Moreover, the addition of a single intrapartum dose of tenofovir/emtricitabine to sc-ZDV and SDNVP significantly reduced the prevalence of NNRTI-associated mutations in mothers at 6 weeks postpartum [39 ] . Further studies are needed to determine the optimal time for treatment initiation with NNRTI-based HAART and the effect of NNRTI-associated mutations on subsequent treatment with HAART.
Malaria coinfection and the risk of mother-to-child transmission in resource-limited countries
The risk of MTCT of HIV associated with HSV-2 coinfection or other sexually transmitted infections (e.g., infections resulting in genital ulcers) described above applies also to transmissions in resource-limited settings. Moreover, in some resource-limited countries, there are endemic infectious diseases that may have an impact on MTCT of HIV. There are conflicting reports on the effect of malaria during pregnancy on MTCT. A recent study found that placental malaria was associated with increased MTCT, even at low maternal viral loads [40 ] . The authors suggested that prevention of malaria during pregnancy in malaria-endemic areas should be part of PMTCT programs. Further research is needed to characterize the association between malaria and MTCT.
Feeding practices and mother-to-child transmission
The WHO recommends exclusive breast-feeding in settings where replacement feeding is not acceptable, feasible, affordable, sustainable, and safe [20] . Breast-feeding is known to offer protection against diarrheal and respiratory diseases that contribute to the high rates of infant mortality in resource-limited countries. To balance the protective effect of breast-feeding with the potential risk of transmission of HIV, there have been several studies on the optimum duration of breast-feeding. In a math-ematical model based on data from Uganda and Kenya, researchers found that reducing exclusive breast-feeding delayed the time to death rather than reducing it altogether; breast-feeding reduced mortality at very young ages; however, infants who got infected progressed rapidly to AIDS, with most dying by 2 years of age [41 ]. Lehman et al. [42 ] found that sc-ARVs used in PMTCT reduced the cell-free virus in the breast milk to a greater extent than the cell-associated virus in breast milk. These and other ongoing studies will have an impact on future recommendations on appropriate feeding practices in resource-limited settings to prevent MTCT.
Lack of PCR-based diagnosis for pediatric HIV
In most resource-limited countries, PCR-based assays are not available for the early diagnosis of pediatric HIV. The high mortality rate of pediatric HIV in resource-limited countries is partly due to the lack of early diagnosis and low coverage of pediatric HAART treatment. There is an urgent need to integrate low-cost and accessible viral nucleic acid-based assays [43 ,44 ] .
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Conclusion
Much progress has been made in the PMTCT; however, challenges that threaten to reverse the gains remain. Resource-rich countries should be unrelenting in their efforts to provide access to HIV testing to all women and PMTCT to HIV-infected pregnant women. Furthermore, access to comprehensive PMTCT, including antiretroviral treatment for HIV-infected women and children, should be paramount in resource-limited countries. 
